ArticleReviews in urology2018
Nocturia: Evaluation and Current Management Strategies.
Article in Reviews in urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Article
- Observational
- Translation and Validation of the Persian ICIQ Nocturia and Nocturia Quality of Life.International urogynecology journal · 2026Article
- Endogenous vasopressin and vasopressin receptor 2 in bladder as anti-diuretic / anti-spasmodic targets for the treatment of multifactorial nocturia.Continence (Amsterdam, Netherlands) · 2025Article
- Decreased nitric oxide production is a novel therapeutic target for salt-induced nocturnal polyuria in aging.Scientific reports · 2025Article
- Risk factors for hyponatremia associated with desmopressin use.Translational andrology and urology · 2024Article
- Association of nocturia with cardiovascular and all-cause mortality: a prospective cohort study with up to 31 years of follow-up.Frontiers in public health · 2023Article
- The Efficacy of Compression Stockings on Patients With Nocturia: A Single-Arm Pilot Study.Cureus · 2022Article
- Dietary salt with nitric oxide deficiency induces nocturnal polyuria in mice via hyperactivation of intrarenal angiotensin II-SPAK-NCC pathway.Communications biology · 2022Article
- Urinary metabolites identified using metabolomic analysis as potential biomarkers of nocturia in elderly men.World journal of urology · 2020Observational
- Desmopressin and the risk of hyponatremia: A population-based cohort study.PLoS medicine · 2019Article
- Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2019Review
- Nocturia in Patients With Multiple Sclerosis.Reviews in urology · 2019Article
- Aging increases the expression of vasopressin receptors in both the kidney and urinary bladder.Neurourology and urodynamics · 2019Article
- Nocturia: Finding an Identity.Reviews in urology · 2018Article
- Pharmacologic management of nocturnal polyuria: a contemporary assessment of efficacy, safety, and progress toward individualized treatment.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nocturia is a complex condition that not only significantly affects quality of life, but may be an indicator of systemic disease. Initial assessment includes a detailed history and physical examination and completion of a frequency volume chart to help identify underlying causes, such as sleep disorders, bladder storage disorders, and polyuria. Treatment with alpha-blockers or antimuscarinic medications may help if the underlying cause is determined to be benign prostatic hyperplasia or overactive bladder, respectively. Treatment options for nocturnal polyuria have been limited to behavioral therapy and off-label use of timed diuretics and desmopressin. Desmopressin acetate nasal spray (Noctiva™, Avadel Pharmaceuticals, Chesterfield, MO) was approved by the US Food and Drug Administration in 2017 for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least twice nightly and has shown efficacy in reducing nocturnal voids by ≥50% in up to 49% of patients in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.